Regeneron Pharma announced earnings per share of $7.16 on revenue of $1.95B. Analysts polled by Investing.com anticipated EPS of $5.91 on revenue of $1.73B.
Regeneron Pharma shares are down 12% from the beginning of the year, still down 2.44% from its 52 week high of $664.64 set on July 20. They are under-performing the S&P 500 which is up 2.34% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.43B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar